Back to Newsroom

The EMA and FDA Grant Orphan Drug Designation to Pharnext’s PXT-3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A

PARIS, June 23, 2014Pharnext SAS today announced that the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designation to PXT-3003 for the treatment of Charcot-Marie-Tooth disease type 1A (CMT 1A).

Click here to read more